Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 6:15:1292347.
doi: 10.3389/fphar.2024.1292347. eCollection 2024.

Clinical characteristics and risk factors analysis of 505 cases of infusion reactions in a tertiary hospital

Affiliations

Clinical characteristics and risk factors analysis of 505 cases of infusion reactions in a tertiary hospital

Weiwei Yin et al. Front Pharmacol. .

Abstract

Background: The clinical characteristics and risk factors of infusion reactions (IRs) are inadequately described in clinical practice due to underreported cases. In the present study, we reported the current status of IRs based on an in-hospital pharmacovigilance database of a tertiary care hospital. Methods: Our study conducted a retrospective analysis of drug-induced IRs recorded at an in-hospital pharmacovigilance center between January 2015 to December 2019. The descriptive statistical analysis encompassed main causative agents, clinical manifestations, organ/system involvement and outcome. The severity of IRs was assessed with reference to the CTCAE version 5.0 criteria and we investigated risk factors associated with severe IRs. Results: During the study period, a total of 505 cases of inpatient drug-induced IRs were detected, of which 79.2% (400 cases) were classified as general IRs and 20.8% (105 cases) were categorized as severe IRs. The primary drugs responsible for these reactions were antibiotics (23%, 116 cases), with piperacillin sodium-sulbactam sodium being the most prevalent, followed by antineoplastic agents (18.4%, 93 cases) and traditional Chinese medicine injections (TCMIs) (12.9%, 65 cases). The administration of cefoperazone - sulbactam, mannatide, Shenqi Fuzheng, elemene, and diterpene ginkgolides meglumine resulted in a higher incidence of critical IRs. Among all cases of IRs, 43.2%, 41.2%, and 23.4% showed signs and symptoms of circulation, skin mucosa, and respiratory organs/systems, respectively. 9.1% of cases experienced systemic damage, while 7.1% and 5.9% of cases reported neurological and gastrointestinal related adverse reactions, respectively. The multivariate analysis revealed that alcohol consumption (OR = 2.389%, 95% CI 1.141-5.002, p = 0.021), age over 65 (OR = 1.814%, 95% CI 1.052-3.127, p = 0.032) and the utilization of contrast media (OR = 4.072%, 95% CI 1.903-8.713, p < 0.001) were identified as risk factors for the development of severe IRs. Conclusion: Understanding the clinical characteristics of IRs helps to implement effective pharmaceutical monitoring and appropriate preventive measures for susceptible populations with risk factors.

Keywords: clinical characteristics; infusion reactions; pharmacovigilance; risk factors; tertiary hospital.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart of case selection.
FIGURE 2
FIGURE 2
Organ/system involvement in IRs.
FIGURE 3
FIGURE 3
Symptoms and signs of IRs. *p < 0.05 compare with total patients. TCMI, Traditional Chinese medicine injection.
FIGURE 4
FIGURE 4
Changes in eosinophil count. A, Baseline level before IRs. B, Time level of IRs. C, Level after IRs.

Similar articles

References

    1. Almuhizi F., De Las Vecillas Sanchez L., Gilbert L., Copaescu A. M., Isabwe G. A. C. (2022). Premedication protocols to prevent hypersensitivity reactions to chemotherapy: a literature review. Clin. Rev. Allergy Immunol. 62 (3), 534–547. 10.1007/s12016-022-08932-2 - DOI - PubMed
    1. Alvarez-Arango S., Ogunwole S. M., Sequist T. D., Burk C. M., Blumenthal K. G. (2021). Vancomycin infusion reaction - moving beyond "red man syndrome. N. Engl. J. Med. 384 (14), 1283–1286. 10.1056/NEJMp2031891 - DOI - PMC - PubMed
    1. Awad A., Goh M. S., Trubiano J. A. (2023). Drug reaction with eosinophilia and systemic symptoms: a systematic review. J. Allergy Clin. Immunol. Pract. 11, 1856–1868. 10.1016/j.jaip.2023.02.035 - DOI - PubMed
    1. Baldo B. A. (2013). Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology 2 (10), e26333. 10.4161/onci.26333 - DOI - PMC - PubMed
    1. Baraf H. S., Yood R. A., Ottery F. D., Sundy J. S., Becker M. A. (2014). Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J. Clin. Rheumatol. 20 (8), 427–432. 10.1097/rhu.0000000000000200 - DOI - PMC - PubMed

LinkOut - more resources